We are analyzing https://link.springer.com/article/10.1007/s10549-010-0849-4.

Title:
Role of ferritin alterations in human breast cancer cells | Breast Cancer Research and Treatment
Description:
Breast cancer is the most common malignancy in women. Successful treatment of breast cancer relies on a better understanding of the molecular mechanisms involved in breast cancer initiation and progression. Recent studies have suggested a crucial role of perturbations in ferritin levels and tightly associated with this, the deregulation of intracellular iron homeostasis; however, the underlying molecular mechanisms for the cancer-linked ferritin alterations remain largely unknown and often with conflicting conclusions. Therefore, this study was undertaken to define the role of ferritin in breast cancer. We determined that human breast cancer cells with an epithelial phenotype, such as MCF-7, MDA-MB-361, T-47D, HCC70 and cells, expressed low levels of ferritin light chain, ferritin heavy chain, transferrin, transferring receptor, and iron-regulatory proteins 1 and 2. In contrast, expression of these proteins was substantially elevated in breast cancer cells with an aggressive mesenchymal phenotype, such as Hs-578T, BT-549, and especially MDA-MB-231 cells. The up-regulation of ferritin light chain and ferritin heavy chain in MDA-MB-231 cells was accompanied by alterations in the subcellular distribution of these proteins as characterized by an increased level of nuclear ferritin and a lower level of the cellular labile iron pool as compared to MCF-7 cells. We established that ferritin heavy chain is a target of miRNA miR-200b, suggesting that its up-regulation in MDA-MB-231 cells may be triggered by the low expression of miR-200b. Ectopic up-regulation of miR-200b by transfection of MDA-MB-231 cells with miR-200b substantially decreased the level of ferritin heavy chain. More importantly, miR-200b-induced down-regulation of ferritin was associated with an increased sensitivity of the MDA-MB-231 cells to the chemotherapeutic agent doxorubicin. These results suggest that perturbations in ferritin levels are associated with the progression of breast cancer toward a more advanced malignant phenotype.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

article, cancer, pubmed, google, scholar, cas, breast, ferritin, cells, iron, human, expression, cell, role, chain, res, resistance, research, alterations, mdamb, heavy, access, genes, privacy, cookies, content, carcinoma, biol, data, information, publish, search, treatment, shpyleva, tryndyak, pogribny, progression, epithelial, receptor, increased, mirb, drug, treat, family, baldi, log, journal, study, april, svitlana,

Topics {✒️}

month download article/chapter node-positive breast cancer iron-dependent cell death hemin-treated leukemia cells cutaneous t-cell lymphoma ferritin h-chain mrna mir-200b substantially decreased restore e-cadherin expression h-ferritin subunit overexpression full article pdf intracellular iron homeostasis related subjects breast cancer cells privacy choices/manage cookies microrna-200 family alterations human term placenta breast cancer relies breast cancer initiation metastatic breast cancer labile iron pool ferritin heavy chain modulating cell growth elevated ferritin production e-cadherin transcriptional mir-205 regulate epithelial estrogen-induced cancer erythroid cells reduces ferritin light chain excess iron play maternal iron status potent iron chelators cdna array study mda-mb-231 cells mirna mir-200b mir-200b-induced tissues ferritin concentration tissue ferritin concentration european economic area athena starlard-davenport chemotherapeutic agent doxorubicin histopathological prognostic indicators van deventer sjh anti-tumour agents kupiec-weglinski jw ischemia reperfusion injury hypericin-mediated regulation check access instant access drug-resistant phenotypes epithelial-mesenchymal transition

Questions {❓}

Huang X (2008) Does iron have a role in breast cancer?
Kabat GC, Rohan TE (2007) Does excess iron play a role in breast carcinogenesis?
Kwok JC, Richardson DR (2002) The iron metabolism of neoplastic cells: alterations that facilitate proliferation?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Role of ferritin alterations in human breast cancer cells
         description:Breast cancer is the most common malignancy in women. Successful treatment of breast cancer relies on a better understanding of the molecular mechanisms involved in breast cancer initiation and progression. Recent studies have suggested a crucial role of perturbations in ferritin levels and tightly associated with this, the deregulation of intracellular iron homeostasis; however, the underlying molecular mechanisms for the cancer-linked ferritin alterations remain largely unknown and often with conflicting conclusions. Therefore, this study was undertaken to define the role of ferritin in breast cancer. We determined that human breast cancer cells with an epithelial phenotype, such as MCF-7, MDA-MB-361, T-47D, HCC70 and cells, expressed low levels of ferritin light chain, ferritin heavy chain, transferrin, transferring receptor, and iron-regulatory proteins 1 and 2. In contrast, expression of these proteins was substantially elevated in breast cancer cells with an aggressive mesenchymal phenotype, such as Hs-578T, BT-549, and especially MDA-MB-231 cells. The up-regulation of ferritin light chain and ferritin heavy chain in MDA-MB-231 cells was accompanied by alterations in the subcellular distribution of these proteins as characterized by an increased level of nuclear ferritin and a lower level of the cellular labile iron pool as compared to MCF-7 cells. We established that ferritin heavy chain is a target of miRNA miR-200b, suggesting that its up-regulation in MDA-MB-231 cells may be triggered by the low expression of miR-200b. Ectopic up-regulation of miR-200b by transfection of MDA-MB-231 cells with miR-200b substantially decreased the level of ferritin heavy chain. More importantly, miR-200b-induced down-regulation of ferritin was associated with an increased sensitivity of the MDA-MB-231 cells to the chemotherapeutic agent doxorubicin. These results suggest that perturbations in ferritin levels are associated with the progression of breast cancer toward a more advanced malignant phenotype.
         datePublished:2010-04-13T00:00:00Z
         dateModified:2010-04-13T00:00:00Z
         pageStart:63
         pageEnd:71
         sameAs:https://doi.org/10.1007/s10549-010-0849-4
         keywords:
            Breast cancer
            Ferritin
            Iron
            MicroRNA miR-200
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig5_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:126
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Svitlana I. Shpyleva
               affiliation:
                     name:National Center for Toxicological Research
                     address:
                        name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                        type:PostalAddress
                     type:Organization
                     name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
                     address:
                        name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Volodymyr P. Tryndyak
               affiliation:
                     name:National Center for Toxicological Research
                     address:
                        name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Olga Kovalchuk
               affiliation:
                     name:University of Lethbridge
                     address:
                        name:Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Athena Starlard-Davenport
               affiliation:
                     name:National Center for Toxicological Research
                     address:
                        name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vasyl’ F. Chekhun
               affiliation:
                     name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
                     address:
                        name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Frederick A. Beland
               affiliation:
                     name:National Center for Toxicological Research
                     address:
                        name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Igor P. Pogribny
               affiliation:
                     name:National Center for Toxicological Research
                     address:
                        name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Role of ferritin alterations in human breast cancer cells
      description:Breast cancer is the most common malignancy in women. Successful treatment of breast cancer relies on a better understanding of the molecular mechanisms involved in breast cancer initiation and progression. Recent studies have suggested a crucial role of perturbations in ferritin levels and tightly associated with this, the deregulation of intracellular iron homeostasis; however, the underlying molecular mechanisms for the cancer-linked ferritin alterations remain largely unknown and often with conflicting conclusions. Therefore, this study was undertaken to define the role of ferritin in breast cancer. We determined that human breast cancer cells with an epithelial phenotype, such as MCF-7, MDA-MB-361, T-47D, HCC70 and cells, expressed low levels of ferritin light chain, ferritin heavy chain, transferrin, transferring receptor, and iron-regulatory proteins 1 and 2. In contrast, expression of these proteins was substantially elevated in breast cancer cells with an aggressive mesenchymal phenotype, such as Hs-578T, BT-549, and especially MDA-MB-231 cells. The up-regulation of ferritin light chain and ferritin heavy chain in MDA-MB-231 cells was accompanied by alterations in the subcellular distribution of these proteins as characterized by an increased level of nuclear ferritin and a lower level of the cellular labile iron pool as compared to MCF-7 cells. We established that ferritin heavy chain is a target of miRNA miR-200b, suggesting that its up-regulation in MDA-MB-231 cells may be triggered by the low expression of miR-200b. Ectopic up-regulation of miR-200b by transfection of MDA-MB-231 cells with miR-200b substantially decreased the level of ferritin heavy chain. More importantly, miR-200b-induced down-regulation of ferritin was associated with an increased sensitivity of the MDA-MB-231 cells to the chemotherapeutic agent doxorubicin. These results suggest that perturbations in ferritin levels are associated with the progression of breast cancer toward a more advanced malignant phenotype.
      datePublished:2010-04-13T00:00:00Z
      dateModified:2010-04-13T00:00:00Z
      pageStart:63
      pageEnd:71
      sameAs:https://doi.org/10.1007/s10549-010-0849-4
      keywords:
         Breast cancer
         Ferritin
         Iron
         MicroRNA miR-200
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-010-0849-4/MediaObjects/10549_2010_849_Fig5_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:126
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Svitlana I. Shpyleva
            affiliation:
                  name:National Center for Toxicological Research
                  address:
                     name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                     type:PostalAddress
                  type:Organization
                  name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
                  address:
                     name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Volodymyr P. Tryndyak
            affiliation:
                  name:National Center for Toxicological Research
                  address:
                     name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Olga Kovalchuk
            affiliation:
                  name:University of Lethbridge
                  address:
                     name:Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Athena Starlard-Davenport
            affiliation:
                  name:National Center for Toxicological Research
                  address:
                     name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vasyl’ F. Chekhun
            affiliation:
                  name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
                  address:
                     name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Frederick A. Beland
            affiliation:
                  name:National Center for Toxicological Research
                  address:
                     name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Igor P. Pogribny
            affiliation:
                  name:National Center for Toxicological Research
                  address:
                     name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:126
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:National Center for Toxicological Research
      address:
         name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
         type:PostalAddress
      name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
      address:
         name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
         type:PostalAddress
      name:National Center for Toxicological Research
      address:
         name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
         type:PostalAddress
      name:University of Lethbridge
      address:
         name:Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada
         type:PostalAddress
      name:National Center for Toxicological Research
      address:
         name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
         type:PostalAddress
      name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
      address:
         name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
         type:PostalAddress
      name:National Center for Toxicological Research
      address:
         name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
         type:PostalAddress
      name:National Center for Toxicological Research
      address:
         name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Svitlana I. Shpyleva
      affiliation:
            name:National Center for Toxicological Research
            address:
               name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
               type:PostalAddress
            type:Organization
            name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
            address:
               name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
               type:PostalAddress
            type:Organization
      name:Volodymyr P. Tryndyak
      affiliation:
            name:National Center for Toxicological Research
            address:
               name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
               type:PostalAddress
            type:Organization
      name:Olga Kovalchuk
      affiliation:
            name:University of Lethbridge
            address:
               name:Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada
               type:PostalAddress
            type:Organization
      name:Athena Starlard-Davenport
      affiliation:
            name:National Center for Toxicological Research
            address:
               name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
               type:PostalAddress
            type:Organization
      name:Vasyl’ F. Chekhun
      affiliation:
            name:R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
            address:
               name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
               type:PostalAddress
            type:Organization
      name:Frederick A. Beland
      affiliation:
            name:National Center for Toxicological Research
            address:
               name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
               type:PostalAddress
            type:Organization
      name:Igor P. Pogribny
      affiliation:
            name:National Center for Toxicological Research
            address:
               name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
      name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
      name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
      name:Department of Biological Sciences, University of Lethbridge, Lethbridge, Canada
      name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
      name:Department of Mechanisms of Anticancer Therapy, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine
      name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
      name:Division of Biochemical Toxicology, National Center for Toxicological Research, Jefferson, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(155)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.6s.

LINK . SPRINGER . COM {}